Key facts
- It has raised $140K; the latest was Early Stage VC ($140K) in Jan 2025.
- Notable investors include Amirkabir Research and Technology Fund.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for FarmoGene
- ·The full record, as it builds
Funding rounds
No funding rounds for FarmoGene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FarmoGene
Provider of genomic testing and breeding improvement services designed to enhance livestock productivity and genetic quality. The company offers genomic evaluation for dairy cattle, sperm cataloging, multiple-birth assessment in sheep, and molecular genetics laboratory services for animal and plant species, enabling livestock farmers and breeders to improve herd performance, health, and economic value through genetic analysis.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Tehran, Iran
- Founded
- 2021
- Employees
- 3
- Website
- farmogene.com/
- Ownership
- Privately Held (backing)
FarmoGene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FarmoGene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FarmoGene in its N-PORT filings yet. We sweep new filings monthly.